Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 7, 2014; 20(9): 2255-2266
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2255
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2255
Management of borderline and locally advanced pancreatic cancer: Where do we stand?
Jin He, Andrew J Page, Matthew Weiss, Christopher L Wolfgang, Timothy M Pawlik, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, United States
Joseph M Herman, Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD 21287, United States
Author contributions: All authors contributed equally to the production of this manuscript.
Correspondence to: Timothy M Pawlik, MD, MPH, PhD, Professor, Department of Surgery, Johns Hopkins Hospital, 600 N. Wolfe Street, Blalock 688, Baltimore, MD 21287, United States. tpawlik1@jhmi.edu
Telephone: +1-410-5022387 Fax: +1-410-5022388
Received: October 28, 2013
Revised: December 10, 2013
Accepted: January 14, 2014
Published online: March 7, 2014
Processing time: 129 Days and 4.1 Hours
Revised: December 10, 2013
Accepted: January 14, 2014
Published online: March 7, 2014
Processing time: 129 Days and 4.1 Hours
Core Tip
Core tip: While the management of resectable patients is surgery (with or without neoadjuvant therapy), and the management of grossly metastatic patients is palliative with systemic chemotherapy with or without radiation, there is an intermediate subset of patients with locally advanced disease which is less straightforward. This review focuses on this unique population of patients with locally advanced pancreatic adenocarcinoma and addresses recent advances and controversies in this field.